Furthermore, multi-gene NGS-based MRD monitoring has recently been applied to AML patients, including those showing NPM1 mutations (Table 1 and Table 2) [41,46,56,60,62,63,65,68,69,73]. The gene discussed is NPM1; the disease is acute myeloid leukemia.